Status:

RECRUITING

A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 Gangliosidosis

Lead Sponsor:

Azafaros A.G.

Conditions:

Niemann-Pick Type C Disease

GM1 Gangliosidosis

Eligibility:

All Genders

4+ years

Phase:

PHASE3

Brief Summary

An 18-month double-blind, randomized, placebo-controlled, multicenter, Phase 3 study to evaluate the safety and efficacy of oral nizubaglustat (AZ-3102) in late-infantile and juvenile forms of Niemann...

Detailed Description

This is a Phase 3 randomized, double-blinded, placebo-controlled study that will evaluate the safety and efficacy of oral nizubaglustat (AZ-3102) in multiple disease areas using a Master Protocol Rese...

Eligibility Criteria

Inclusion Criteria:

  • Male and female participants, aged 4 years and older with a diagnosis of the late-infantile or juvenile form of NPC disease. Detailed inclusion criteria are presented in the NPC disease-specific subprotocol AZA-001-301-NPC (NCT07082725).
  • Male and female participants, aged 4 years and older with a diagnosis of GM1 or GM2 (Tay-Sachs, Sandhoff, or GM2AB variant disease) gangliosidosis of late-infantile/ juvenile onset. Detailed inclusion criteria are presented in the GM1/GM2 gangliosidosis-specific subprotocol AZA-001-301-GMx (NCT07082543).

Exclusion Criteria:

  • Detailed exclusion criteria are presented in the NPC disease-specific subprotocol AZA-001-301-NPC
  • Detailed exclusion criteria are presented in the GM1/GM2 gangliosidosis-specific subprotocol AZA-001-301-GMx

Key Trial Info

Start Date :

June 30 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

November 4 2027

Estimated Enrollment :

147 Patients enrolled

Trial Details

Trial ID

NCT07054515

Start Date

June 30 2025

End Date

November 4 2027

Last Update

April 15 2026

Active Locations (37)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 10 (37 locations)

1

UCSF Children's Hospital and Research Center at Oakland

Oakland, California, United States, 94609

2

University of Minnesota Medical School

Minneapolis, Minnesota, United States, 55455

3

Mayo Clinic Childrens Center - PIN

Rochester, Minnesota, United States, 55905

4

Children's Medical Center Dallas

Dallas, Texas, United States, 75235